
MYPROSTATESCORE 2.0
Clear Results. Confident Decision.
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.
[wpcode id=”521″]
Stay Up To Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
Cancer Today Spotlights Lynx Dx’s MPS2 as a Breakthrough At-Home Prostate Cancer Test
In a recent feature, Cancer Today explores how MyProstateScore 2.0 [...]
Newly Published Analytical Validation Reinforces Accuracy and Precision of MyProstateScore 2.0
A new peer-reviewed study published in Diagnostics confirms the analytical [...]
Bringing Accurate and Flexible Prostate Cancer Insights to AUA2025!
Join the Lynx Dx team at AUA2025, the American Urological Association's annual meeting, April 26-29, 2025.